Zymeworks to Acquire Theravance Biopharma for $929 Million

Zymeworks has agreed to acquire Theravance Biopharma in a deal valued at approximately $929 million. The transaction is seen as part of Zymeworks' strategy to expand its biopharma portfolio. Under the agreement, Zymeworks will purchase Theravance's shares through a mix of cash and stock. The acquisition aims to strengthen Zymeworks' presence in oncology. Theravance Biopharma is known for specializing in respiratory diseases and other therapeutic areas. This merger could accelerate the development of new treatments by combining the research and development resources of both companies. The deal is expected to close in the first quarter of 2024. Following the acquisition, Zymeworks will take over Theravance's existing drug portfolio and clinical trials. Company executives state that this merger will create long-term value for shareholders. This is not investment advice.